Sulfamethoxazole-Trimethoprim 合剤に関する研究

抄録

This report is based on the results of studies on anti-microbial activities of sulfamethoxazole (SMX) -trimethoprim (TMP) combination product against clinically isolated strains and therapeutic efficacy of SMX-TMP combinations in various infections.
1. Minimum inhibitory concentrations (MICs) of SMX and TMP in 20 : 1 combination were clearly potentiated in comparison with those of SMX alone against 17 strains of coagulase-positive Staphylococcus aureus, 58 strains of Escherichia coli and 8 strains of Proteus. MICs of the combinatoin in Pseudomonas strains were similar to those of SMX alone.
2. A clinical trial of SMX-TMP combinations was conducted in 203 patients with infection of the fields of internal medicine, pediatrics, surgery, orthopedics, gynecology, urology and otorhinolaryngology. The daily dosage for adults was 4 to 6 tablets, for children 2 tablets and for infants 1 tablet. The overall effective rate was 63%.
3. Side effects were registered in 12 patients. These included drug exanthema in 6, gastro-intestinal disturbance (diarrhea, epigastralgia, vomiting, anorexia) in 4 and giddiness and restlessness in 1 patient, respectively.